Less than two weeks after Pfizer struck a deal with a Chinese drugmaker to gain commercial rights to a GLP-1 drug, the ...

Taiwan is mapping out a four-year national pharmaceutical resilience preparedness program that aims to bolster the country’s ...

Johnson & Johnson’s standout trial results for its Tecvayli and Darzalex Faspro pairing in previously treated relapsed or ...

Although major pharmaceutical companies have fallen in line with President Donald Trump’s “most favored nation” (MFN) drug pricing agenda, the specifics of their negotiated concessions and the actu | ...

Sanofi has agreed to sell its Medley generics unit in Brazil to leading local drugmaker EMS, according to an announcement from international law firm Mayer Brown, which advised EMS.

As nonprofit-governed Servier continues to make gains with its IDH-mutant glioma med Voranigo, the drugmaker is wading deeper into the rare oncology arena with a new M&A play.  | Servier on Friday ...

Almost all of last month’s top 10 pharma TV ad spenders took advantage of February’s two major sporting events to get the word out about their meds. | Almost all of last month’s top 10 pharma TV ad ...

Kyowa Kirin has decided to discontinue all clinical development of its OX40 drug after two new cancer cases emerged. | Kyowa Kirin has decided to discontinue all clinical development of its OX40 drug ...

As AI and automation reshape drug discovery, laboratories themselves are being forced to evolve. Gensler’s Ryley Poblete joins the podcast to explain how new technologies, the makeup of scientific ...

Forma Life Sciences, which inherited BioDuro’s California production operations earlier this year, has officially ...

One of the most powerful voices in the biopharma industry, Pfizer CEO Albert Bourla, Ph.D., has weighed in with sharp ...

After delivering solid sales growth in a difficult 2025, Germany’s Merck KGaA may have a tougher go of things this year, which the company is crediting in part to a predicted onslaught of U.S.